OLX104C / OliX Pharma - LARVOL DELTA

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia (clinicaltrials.gov) - P1/2 | N=158 | Recruiting | Sponsor: Olix Pharmaceuticals, Inc.

New P1/2 trial • Alopecia • Dermatology • Immunology

[HIT Algong] Olix, androgenetic alopecia new drug clinical phase 1b·2a approved in Australia [Google translation] (HIT News) - "The Belbury Australian Human Research Ethics Committee approved the plan for a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose phase 1b/2a clinical trial to evaluate the safety and efficacy of OLX72021 in healthy men with androgenetic alopecia."

New P1/2 trial • Alopecia

Olix, Hair Loss Treatment 'OLX104C' Phase 1b/2a IND Submission in Australia [Google translation] (HIT News) - "Olix...announced on the 12th that it had submitted a phase 1b/2a clinical trial plan for its hair loss treatment candidate substance 'OLX104C (substance name OLX72021)' to the Belbury Human Research Ethics Committee (HREC) in Australia...This Phase 1b/2a clinical trial will evaluate the safety and efficacy of OLX104C in healthy men with androgenetic alopecia (male pattern baldness). The clinical trial will be multi-center, randomized, double-blind, placebo-controlled, and multiple-ascending doses, and is scheduled to be conducted for approximately 30 months from the date of approval. It is scheduled to be conducted at approximately 10 clinical trial sites in Australia, and the target number of enrolled subjects is 120."

New P1/2 trial • Alopecia

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OLX72021 in Healthy Males with Androgenetic Alopecia. (ANZCTR) - P1 | N=30 | Completed | Sponsor: OLIX AU PTY LTD | Recruiting ➔ Completed

Trial completion • Alopecia • Dermatology • Immunology • AR

A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OLX72021 in Healthy Males with Androgenetic Alopecia. (ANZCTR) - P1 | N=30 | Recruiting | Sponsor: OLIX AU PTY LTD | Initiation date: Jun 2000 ➔ Jun 2023

Trial initiation date • Alopecia • AR